Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer

Kumamoto,Tomotaka; Yamada,Kohji; Yoshida,Saishu; Aoki,Katsuhiko; Hirooka,Shinichi; Eto,Ken; Yanaga,Katsuhiko; Yoshida,Kiyotsugu

doi:10.3892/ijo.2020.5020

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer

Authors:
- Tomotaka Kumamoto
- Kohji Yamada
- Saishu Yoshida
- Katsuhiko Aoki
- Shinichi Hirooka
- Ken Eto
- Katsuhiko Yanaga
- Kiyotsugu Yoshida
View Affiliations

Affiliations: Department of Biochemistry, The Jikei University School of Medicine, Tokyo 105‑8461, Japan, Department of Pathology, The Jikei University School of Medicine, Tokyo 105‑8461, Japan, Department of Surgery, The Jikei University School of Medicine, Tokyo 105‑8461, Japan
Published online on: March 20, 2020 https://doi.org/10.3892/ijo.2020.5020
Pages: 1529-1539

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dual specificity tyrosine‑phosphorylation‑regulated kinase 2 (DYRK2) is a protein kinase that functions as a novel tumor suppressor. Previous studies have reported that DYRK2 expression is decreased in colorectal cancer compared with adjacent non‑tumor tissues. However, the regulatory mechanisms by which the expression of DYRK2 is diminished remain unknown. The aim of the present study was to determine the regulatory mechanisms of DYRK2 expression. The present study identified the promoter regions of the DYRK2 gene and demonstrated that they contained CpG islands in human cancer cells. In addition, the DYRK2 promoter region exhibited a higher level of methylation in colorectal cancer tissues compared with healthy tissues from clinical samples. DYRK2 expression was increased at the mRNA and protein level in colorectal cancer cell lines by treatment with 5‑Azacytidine, a demethylating agent. The results further demonstrated that knockdown of DNA methyltransferase (DNMT) 1 elevated DYRK2 expression in colorectal cancer cell lines. A colitis‑related mouse carcinogenesis model also exhibited a lower DYRK2 level in colorectal cancer tissues compared with adjacent non‑tumor tissues. In this model, nuclear staining of DNMT1 was detected in colorectal cancer cells, whereas a cytoplastic distribution pattern of DNMT1 staining was exhibited in healthy tissue. Overall, these findings suggested that DYRK2 expression was downregulated via transcriptional regulation by DNMT1 to elevate the proliferation of colorectal cancer cells.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Fearon ER and Vogelsteine B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
3	Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 17:79–92. 2017. View Article : Google Scholar : PubMed/NCBI
4	Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E and Flowers CR: Metastatic colorectal cancer: A systematic review of the value of current therapies. Clin Colorectal Cancer. 15:1–6. 2016. View Article : Google Scholar :
5	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
7	Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 244:254–259. 2006. View Article : Google Scholar : PubMed/NCBI
8	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
9	Simó-Riudalbas L and Esteller M: Cancer genomics identifies disrupted epigenetic genes. Hum Genet. 133:713–725. 2014. View Article : Google Scholar
10	Berg M and Søreide K: Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci. 12:9426–9439. 2011. View Article : Google Scholar
11	Baylin SB and Jones PA: Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 8:pii: a019505. 2016. View Article : Google Scholar : PubMed/NCBI
12	Feinberg AP: The key role of epigenetics in human disease prevention and mitigation. N Engl J Med. 378:1323–1334. 2018. View Article : Google Scholar : PubMed/NCBI
13	Miremadi A, Oestergaard MZ, Pharoah PD and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet. 16:R28–R49. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ferguson-Smith AC and Greally JM: Epigenetics: Perceptive enzymes. Nature. 449:148–149. 2007. View Article : Google Scholar : PubMed/NCBI
15	Søreide K: Chapter 34 - Cancer Epigenetics In: Handbook of Epigenetics. 2nd Edition. Academic Press; 2017
16	Nihira NT and Yoshida K: Engagement of DYRK2 in proper control for cell division. Cell Cycle. 14:802–807. 2015. View Article : Google Scholar : PubMed/NCBI
17	Taira N, Nihira K, Yamaguchi T, Miki Y and Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 25:725–738. 2007. View Article : Google Scholar : PubMed/NCBI
18	Yoshida K: Nuclear trafficking of pro-apoptotic kinases in response to DNA damage. Trends Mol Med. 14:305–313. 2008. View Article : Google Scholar : PubMed/NCBI
19	Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y and Yoshida K: DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest. 122:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
20	Maddika S and Chen J: Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol. 11:409–419. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jung HY, Wang X, Jun S and Park JI: Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation. J Biol Chem. 288:7252–7262. 2013. View Article : Google Scholar : PubMed/NCBI
22	Mimoto R, Taira N, Takahashi H, Yamaguchi T and Okabe M: DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. Cancer Lett. 339:214–225. 2013. View Article : Google Scholar : PubMed/NCBI
23	Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M, Kawano Y, Takeno S, Yamamoto S and Kawahara K: DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. Anticancer Res. 29:2753–2757. 2009.PubMed/NCBI
24	Zhang X, Xu P, Ni W, Fan H, Xu J, Chen Y, Huang W, Lu S, Liang L, Liu J, et al: Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma. Pathol Res Pract. 212:162–170. 2016. View Article : Google Scholar : PubMed/NCBI
25	Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z, Koeffler HP and Yin D: Low expression of dyrk2 (dual specificity tyrosine phosphorylation regulated Kinase 2) correlates with poor prognosis in colorectal cancer. PLoS One. 11:e01599542016. View Article : Google Scholar : PubMed/NCBI
26	Ito D, Yogosawa S, Mimoto R, Hirooka S, Horiuchi T, Eto K, Yanaga K and Yoshida K: Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer. Cancer Sci. 108:1565–1573. 2017. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition. Springer; New York: 2017, View Article : Google Scholar
29	Komashko VM and Farnham PJ: 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics. 5:229–240. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kim M, Miyamoto S, Sugie S, Yasui Y, Ishigamori-Suzuki R, Murakami A, Nakagama H and Tanaka T: A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice. In Vivo. 22:557–563. 2008.PubMed/NCBI
31	Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S and Mori H: A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94:965–973. 2003. View Article : Google Scholar : PubMed/NCBI
32	Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T and Rahman KM: Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact. 177:128–136. 2009. View Article : Google Scholar
33	Yasui Y, Hosokawa M, Mikami N, Miyashita K and Tanaka T: Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact. 193:79–87. 2011. View Article : Google Scholar : PubMed/NCBI
34	Miyoshi N, Nagasawa T, Mabuchi R, Yasui Y, Wakabayashi K, Tanaka T and Ohshima H: Chemoprevention of azoxymethane/dextran sodium sulfate-induced mouse colon carcinogenesis by freeze-dried yam sanyaku and its constituent diosgenin. Cancer Prev Res (Phila). 4:924–934. 2011. View Article : Google Scholar
35	Mimoto R, Imawari Y, Hirooka S, Takeyama H and Yoshida K: Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer. Oncogene. 36:1862–1872. 2017. View Article : Google Scholar
36	Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 20:2429–2440. 2002. View Article : Google Scholar : PubMed/NCBI
37	Gnyszka A, Jastrzebski Z and Flis S: DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 33:2989–2996. 2013.PubMed/NCBI
38	Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
39	Probst AV, Dunleavy E and Almouzni G: Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 10:192–206. 2009. View Article : Google Scholar : PubMed/NCBI
40	He S, Wang F, Yang L, Guo C, Wan R, Ke A, Xu L and Hu G: Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PLoS One. 6:e276842011. View Article : Google Scholar : PubMed/NCBI
41	Rajendran G, Shanmuganandam K, Bendre A, Muzumdar D, Goel A and Shiras A: Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol. 104:483–494. 2011. View Article : Google Scholar : PubMed/NCBI
42	Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001. View Article : Google Scholar : PubMed/NCBI
43	Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA and Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27:2291–2298. 1999. View Article : Google Scholar : PubMed/NCBI
44	Lee YC, Lee YL, Chuang JP and Lee JC: Differences in survival between colon and rectal cancer from SEER data. PLoS One. 8:e787092013. View Article : Google Scholar : PubMed/NCBI